Are Analysts Bullish about Exact Sciences Corporation (NASDAQ:EXAS) after last week?

Exact Sciences Corporation (NASDAQ:EXAS) Logo
Investors sentiment decreased to 1.26 in Q2 2019. Its down 0.03, from 1.29 in 2019Q1. It dropped, as 31 investors sold Exact Sciences Corporation shares while 113 reduced holdings. 76 funds opened positions while 106 raised stakes. 108.62 million shares or 14.41% less from 126.90 million shares in 2019Q1 were reported.
Fred Alger Mngmt holds 694,129 shares. State Of Alaska Department Of Revenue has 0.03% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 14,019 shares. Coastline Tru reported 4,500 shares. Spark Investment Mngmt Ltd Co stated it has 57,700 shares. Fulton Bancorporation Na stated it has 0.02% in Exact Sciences Corporation (NASDAQ:EXAS). Axiom International De holds 0.66% or 205,496 shares. Csat Invest Advisory L P holds 0.06% or 1,541 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) has 0.03% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 25,703 shares. Boston Advsrs Ltd Liability Com accumulated 0.11% or 16,696 shares. Caxton Assocs L P accumulated 2,281 shares. Moors And Cabot accumulated 1,825 shares or 0.03% of the stock. Fisher Asset Limited invested in 0.01% or 68,150 shares. Mitsubishi Ufj Tru & reported 0.04% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Zevenbergen Cap Investments Limited Company reported 6.76% in Exact Sciences Corporation (NASDAQ:EXAS). Envestnet Asset Mngmt owns 24,010 shares for 0% of their portfolio.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 3 analysts covering EXACT Sciences (NASDAQ:EXAS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. EXACT Sciences has $14300 highest and $11000 lowest target. $124.33’s average target is 16.51% above currents $106.71 stock price. EXACT Sciences had 6 analyst reports since March 15, 2019 according to SRatingsIntel. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by UBS on Thursday, August 1. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Goldman Sachs on Friday, April 12. The firm has “Buy” rating given on Tuesday, April 16 by UBS. UBS maintained the shares of EXAS in report on Wednesday, May 1 with “Buy” rating. The firm has “Buy” rating given on Wednesday, May 1 by Canaccord Genuity. Below is a list of Exact Sciences Corporation (NASDAQ:EXAS) latest ratings and price target changes.

01/08/2019 Broker: UBS Rating: Buy Old Target: $120.0000 New Target: $143.0000 Maintain
01/05/2019 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $115.0000 New Target: $120.0000 Maintain
01/05/2019 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $100.0000 New Target: $110.0000 Maintain
16/04/2019 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $109 New Target: $115 Maintain
12/04/2019 Broker: Goldman Sachs Old Rating: Buy New Rating: Buy New Target: $120 Maintain
15/03/2019 Broker: BidaskScore Rating: Buy Upgrade

The stock decreased 1.82% or $1.98 during the last trading session, reaching $106.71. About 1.03 million shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 100.54% since September 13, 2018 and is uptrending. It has outperformed by 100.54% the S&P500.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $13.77 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

More notable recent Exact Sciences Corporation (NASDAQ:EXAS) news were published by: Finance.Yahoo.com which released: “Is Exact Sciences (NASDAQ:EXAS) Weighed On By Its Debt Load? – Yahoo Finance” on September 05, 2019, also Nasdaq.com with their article: “Why Exact Sciences Is Sinking and Genomic Health Is Rising – Nasdaq” published on July 29, 2019, Nasdaq.com published: “Interesting EXAS Put And Call Options For January 2019 – Nasdaq” on November 29, 2018. More interesting news about Exact Sciences Corporation (NASDAQ:EXAS) were released by: Nasdaq.com and their article: “EXACT Sciences is Now Oversold (EXAS) – Nasdaq” published on December 21, 2018 as well as Seekingalpha.com‘s news article titled: “Exact Sciences Is An Attractive Cancer Diagnostics Pick – Seeking Alpha” with publication date: August 28, 2019.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.